Wall Street analyst estimates for PolyPid Ltd. (PYPD): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials.
Valuation Ratios
| Price / Book | 21.89 |
| EV / EBITDA | -3.18 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $127000 | $205000 | $411000 | $947000 | $1.0M | $1.1M | $1.7M | 0 | 0 | 0 |
| Gross Profit | -$127000 | -$205000 | -$411000 | -$947000 | -$1.0M | -$1.1M | -$1.7M | 0 | 0 | 0 |
| Research & Development | $7.7M | $9.7M | $12.6M | $14.1M | $17.0M | $30.4M | $28.0M | $16.1M | $22.8M | $23.8M |
| Selling, General & Admin | $2.6M | $4.1M | $5.8M | $3.5M | $9.3M | $12.5M | $10.9M | $6.7M | $5.2M | $9.2M |
| Operating Expenses | $10.3M | $13.8M | $18.4M | $17.6M | $25.3M | $42.0M | $37.2M | $22.9M | $28.0M | $33.0M |
| Operating Income | -$10.3M | -$13.8M | -$18.4M | -$18.6M | -$26.3M | -$43.1M | -$38.9M | -$22.9M | -$28.0M | -$33.0M |
| EBITDA | -$10.1M | -$13.6M | -$42.1M | -$5.9M | -$35.9M | -$41.5M | -$36.4M | -$20.3M | -$25.8M | -$31.9M |
| Interest Expense | $108000 | $16000 | $42000 | $15000 | $17000 | 0 | $1.3M | $1.7M | $1.5M | $685000 |
| Pre-tax Income | -$11.4M | -$54.5M | $5.9M | -$6.9M | -$36.9M | -$42.6M | -$39.4M | -$23.8M | -$29.0M | -$34.2M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | $129000 | $69000 | $42000 | $5000 |
| Net Income | -$11.4M | -$54.5M | $5.9M | -$6.9M | -$35.3M | -$40.7M | -$39.5M | -$23.9M | -$29.0M | -$34.2M |
| EPS | $-77.48 | $-370.58 | $26.70 | $-15.03 | $-4.48 | $-67.80 | $-61.20 | $-16.99 | $-4.91 | $-2.09 |
| EPS (Diluted) | $-77.48 | $-370.58 | $26.70 | $-15.03 | $-122.10 | $-67.80 | $-61.20 | $-16.99 | $-4.91 | $-2.09 |
| Shares Outstanding (Diluted) | $588148 | $588148 | $886430 | $886430 | $1.3M | $1.2M | $1.3M | $1.4M | $5.9M | $16.4M |
Price
| Price | $5.21 |
| Market Cap | $99M |
| Exchange | NASDAQ |
| Country | IL |
Related companies: ANVS · ATNM · BCAB · BTAI · CELU · EVAX · MAIA
Explore sector: Healthcare · Biotechnology
More sections of PYPD: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks